002030.SZ
Daan Gene Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 5.39
−3.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 738.0M | 757.7M | 853.0M | 1.2B | 12.0B |
| Cost of Revenue | 499.0M | 512.2M | 532.7M | 584.9M | 3.3B |
| Gross Profit | 239.0M | 245.5M | 320.3M | 596.0M | 8.8B |
| Operating Expenses | |||||
| R&D Expense | 158.1M | 186.3M | 225.7M | 302.3M | 702.4M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 158.3M | 157.8M | 147.1M | 138.3M | 330.8M |
| Selling & Marketing Expense | 223.0M | 223.4M | 208.1M | 172.8M | 939.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 522.9M | 542.7M | 525.3M | 548.5M | 1.9B |
| Cost and Expenses | 1.0B | 1.1B | 1.1B | 1.1B | 5.2B |
| Operating Income (EBIT) | (945.8M) | (753.4M) | (1.1B) | 121.6M | 6.3B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (950.7M) | (757.0M) | (1.1B) | 113.5M | 6.3B |
| Income Tax Expense | (20.7M) | 23.5M | (132.1M) | 41.8M | 891.4M |
| Bottom Line | |||||
| Net Income | (895.5M) | (744.4M) | (925.2M) | 104.7M | 5.4B |
| Earnings from Cont. Ops | (930.0M) | (780.5M) | (939.1M) | 71.7M | 5.4B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (895.5M) | (744.4M) | (925.2M) | 104.7M | 5.4B |
| Per Share | |||||
| Basic EPS | (CN¥0.64) | (CN¥0.53) | (CN¥0.66) | CN¥0.07 | CN¥3.86 |
| Diluted EPS | (CN¥0.64) | (CN¥0.53) | (CN¥0.66) | CN¥0.07 | CN¥3.86 |
| Revenue Per Share | CN¥0.53 | CN¥0.54 | CN¥0.61 | CN¥0.79 | CN¥8.58 |
| Shares | |||||
| Basic Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.5B | 1.4B |
| Diluted Shares Outstanding | 1.4B | 1.4B | 1.4B | 1.5B | 1.4B |
| Profitability Metrics | |||||
| EBITDA | — | (442.1M) | (712.2M) | 475.2M | 6.6B |
| D&A | — | 311.2M | 355.4M | 353.6M | 284.2M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026